multiple

(redirected from multiple sclerosis)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Price-Earnings Ratio

The price of a security per share at a given time divided by its annual earnings per share. Often, the earnings used are trailing 12 month earnings, but some analysts use other forms. The P/E ratio is a way to help determine a security's stock valuation, that is, the fair value of a stock in a perfect market. It is also a measure of expected, but not realized, growth. Companies expected to announce higher earnings usually have a higher P/E ratio, while companies expected to announce lower earnings usually have a lower P/E ratio. See also: PEG

multiple

1. In stock-index futures, the number multiplied by the futures price to determine the value of the contract. For example, the $500 multiple of the Standard & Poor's Midcap Index is multiplied by the futures price to determine the value of one contract. Thus, a futures price of $230 would yield a contract value of $115,000 ($500 × $230).

Multiple.

A stock's multiple is its price-to-earnings ratio (P/E). It's figured by dividing the market price of the stock by the company's earnings.

The earnings could be the actual earnings for the past four quarters, called a trailing P/E. Or they might be the actual figures for the past two quarters plus an analyst's projection for the next two, called a forward P/E.

Investors use the multiple as a way to assess whether the price they are paying for the stock is justified by its earnings potential. The higher the multiple they are willing to accept, the higher their expectations for the stock.

However, some investors reject stocks with higher multiples, since it may be impossible for the stock to meet the market's expectations.

References in periodicals archive ?
Radioisotope studies of neurogenic bladder in multiple sclerosis. J Neurosurg Nurs.
TYSABRI was approved in Japan for the prevention of relapse and delaying the accumulation of physical disability in multiple sclerosis in March 2014, and was launched in June of the same year.
Multiple Sclerosis is an immune-mediated inflammatory/neurodegenerative disorder of human Central Nervous System resulting in demyelination of axons of neurons that affects more than 2 million individuals around the globe.1 The disease is known to mankind since 1830s.2 Even though, MS disease prevalence is maximum in inhabitants from the northern United States, northern Europe, Canada, New Zealand, and southern Australiabut people from all countries and of all races have been diagnosed with the disease.3 In Pakistan, it has been reported that 53% of patients presenting with demyelinating disease have multiple sclerosis.4 Among these patients, relapsing remitting (RR) pattern was seen in 80%, while 20% had secondary progressive multiple sclerosis (SPMS).5
Mostly MS children are severely disabled, either physically or cognitively and half of them are predicted to have the secondary-progressive MS (SPMS).4 Little information exists regarding symptoms and disease progression of paediatric multiple sclerosis in Pakistan.
"Among persons with multiple sclerosis, the brain shrinks markedly faster than normal.
Clinical course and classification of multiple sclerosis. Retrieved from http://www.uptodate.com/contents/clinicalcourse-and-classification-of-multiple-sclerosis?
An awareness of this presentation may lead to a diagnosis of MS in some patients and can be a sign of relapse in patients with established multiple sclerosis.
Exercise training programmes should be considered in the future as possible complements to standard multiple sclerosis treatments, said researchers.
MS occurs in most ethnic groups, including African-Americans, Asians, and Hispanics/Latinos (Multiple Sclerosis Coalition, 2015) and has historically been thought to occur most frequently among Caucasians in Western Europe and North America (DeLuca & Nocentini, 2011).
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry.
[ClickPress, Tue Jun 02 2015] Global Markets Direct's, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2015', provides an overview of the Relapsing Multiple Sclerosis (RMS)'s therapeutic pipeline.
We help with adaptations to help them in their everyday ways, funding short breaks to respite care as well as lots of other things that Multiple Sclerosis brings.

Full browser ?